[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336304-105":59,"doc-detail-336304-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","special-issue-ovarian-cancer-advances-on-pathophysiology-and-therapies-editorial","Special Issue “Ovarian Cancer: Advances on Pathophysiology and Therapies” - Editorial","","Editorial introducing a special issue focused on ovarian cancer, emphasizing the disease’s high mortality driven largely by late diagnosis and chemoresistance, along with metastatic progression. It summarizes selected research articles and reviews covering mechanisms and biomarkers, including oxidative stress and inflammatory lipid signaling, circulating tumor DNA detection, SYNE1 mutation-associated immune signaling, and MRE11 inhibition–mediated synthetic lethality in BRCA2-deficient cells. It also highlights resveratrol effects and discusses ferroptosis and detection roles of SLC7A11 and HE4, plus PROTAC-based therapeutic strategies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/special-issue-ovarian-cancer-advances-on-pathophysiology-and-therapies-editorial/336304/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/special-issue-ovarian-cancer-advances-on-pathophysiology-and-therapies-editorial/336304.png","ImageObject",300,407,{"name":92,"@type":93},"Ivy","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":19},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why does the editorial emphasize chemoresistance and late diagnosis in ovarian cancer outcomes?","Question",{"text":112,"@type":113},"It links high lethality to delayed diagnosis and chemoresistance, noting that chemoresistance substantially worsens disease outcome and contributes to death alongside metastatic disease.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What kinds of biomarker approaches are discussed in the special issue?",{"text":117,"@type":113},"The editorial highlights evaluation of specific biomarkers and reviews research examples such as circulating tumor DNA (ctDNA) and mutation-related biomarkers like SYNE1, as well as the roles of SLC7A11 and HE4.",{"name":119,"@type":110,"acceptedAnswer":120},"Which therapeutic strategies and mechanistic targets are highlighted?",{"text":121,"@type":113},"It summarizes approaches including MRE11 blockade with mirin to induce synthetic lethality in BRCA2-deficient cells, anticancer activity of resveratrol affecting signaling and angiogenesis, and reviews of PROTACs in ovarian cancer.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336304,1793006229,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":19,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":81,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":39,"preview_page_count":81,"preview_urls":144},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","Editorial  \nSpecial Issue “Ovarian Cancer: Advances on Pathophysiology and Therapies”  \nGiovanni Tossetta 1, * and Annalisa Inversetti 2,3, *  \nCitation: Tossetta, G.; Inversetti, A. Special Issue “Ovarian Cancer:  \nAdvances on Pathophysiology and Therapies”. Int. J. Mol. Sci. 2024, 25, 5282. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ijms25105282  \nReceived: 5 May 2024  \nAccepted: 7 May 2024  \nPublished: 13 May 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Experimental and Clinical Medicine, Università Politecnica delle Marche, 60126 Ancona, Italy  \n2 Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072 Milan, Italy  \n3 IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano, Italy  \n* Correspondence: [g.tossetta@univpm.it](g.tossetta@univpm.it) (G.T.); [annalisa.inversetti@hunimed.eu](annalisa.inversetti@hunimed.eu) (A.I.)  \nOvarian cancer is a gynecologic cancer with a high mortality rate, and its incidence has increased significantly over the past 50 years. The high lethality of ovarian cancer, but also other types of cancer, is mainly due to its late diagnosis and to the occurrence of chemoresistance [1–3] . In fact, the occurrence of chemoresistance significantly worsens the outcome of this disease.  \nThe evaluation of the expression of specific biomarkers led to important results for predicting the occurrence/progression of several cancerous [4–10] and noncancerous [11–13] diseases, as well as identifying novel therapeutic targets [14–19] .  \nHowever, despite advances in medical tumor therapy, the occurrence of chemoresistance and metastatic disease are the most common causes of death in patients with ovarian cancer [20,21] . Thus, new therapeutic approaches that can improve diagnosis and treatment outcomes are needed. To achieve this aim, we need a better understanding of the molecular changes occurring in ovarian cancer and the development of molecular biomarkers able to predict tumor behavior and the risk of disease recurrence and chemoresistance.  \nIn this Special Issue, six articles and three reviews addressing the major problems in ovarian cancer pathophysiology and therapies have been selected for publication.  \nThe study by Chacón and colleagues evaluated 112 coding genes upregulated in the aged nulliparous (NP) mouse ovary compared to the aged multiparous one as a control. Canonical gene ontology and pathway analyses showed a pro-oxidant state accompanied by an increased metabolism of inflammatory lipid mediators. Moreover, the authors found an upregulation of typical epithelial cell markers in the aged NP ovary during the pre-neoplastic phase of the mouse ovarian surface epithelial (MOSE) cell line. Thus, the aged NP ovary displays a multifaceted stress state resulting from oxidative imbalance and pro-inflammatory lipid signaling.  \nZhu and colleagues assessed the presence of circulating tumor DNA in the blood (ctDNA) in women diagnosed with serous ovarian cancer and found tumor-specific variants (TSVs) in cancer cells. Moreover, post-surgery plasma showed the presence of ctDNA in 32% of the patients with visible residual disease, while 66% had no visible residual disease, and, of these, 77.4% of patients had detectable ctDNA.  \nIn another study, Harbin and colleagues evaluated the SYNE1 mutation frequency and effects in ovarian cancer and found that of 50 patients, 16 had a SYNE1 mutation, and 15 had recurrent disease. The median TMB for SYNE1-mutated patients was 25 compared to 7 for SYNE1-wild-type patients. Moreover, gene expression related to immune cell trafficking, inflamma","cbCaiafv7CRwXRWK","https://ap.wps.com/l/cbCaiafv7CRwXRWK","pdf",180857,"English","# Editorial\n## Scope and rationale\n## Selected research studies\n## Featured reviews","[{\"question\":\"Why does the editorial emphasize chemoresistance and late diagnosis in ovarian cancer outcomes?\",\"answer\":\"It links high lethality to delayed diagnosis and chemoresistance, noting that chemoresistance substantially worsens disease outcome and contributes to death alongside metastatic disease.\"},{\"question\":\"What kinds of biomarker approaches are discussed in the special issue?\",\"answer\":\"The editorial highlights evaluation of specific biomarkers and reviews research examples such as circulating tumor DNA (ctDNA) and mutation-related biomarkers like SYNE1, as well as the roles of SLC7A11 and HE4.\"},{\"question\":\"Which therapeutic strategies and mechanistic targets are highlighted?\",\"answer\":\"It summarizes approaches including MRE11 blockade with mirin to induce synthetic lethality in BRCA2-deficient cells, anticancer activity of resveratrol affecting signaling and angiogenesis, and reviews of PROTACs in ovarian cancer.\"}]","Special Issue “Ovarian Cancer: Advances on Pathophysiology and Therapies” - Editorial | PDF",1790014477,[145,149,153],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9a1f7cd6d0ff83a9d5fe3ba7cca64c72.webp",983,1390,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/33c0445a97528ea80bfb31d8ccdadd68.webp",982,1388,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/681cd4bc3b4a9495f16b3f011a10c40e.webp",981,1387]